In a study presented at #ASCO2017, more than 500 patients with metastatic solid tumors were studied. The results showed that 72% of the cases found genetic alterations that could indicate use of some specific drug in clinical trials. The most surprising result was that 11% of the patients had germinal changes related to a greater predisposition to cancer, that is, indicative of hereditary cancer. In none of these cases had prior knowledge of the existence of hereditary predisposition. The study concludes that the sequencing of new generation of tumors can identify a significant portion of cases with unanticipated hereditary cancer germ mutations, which will be of big importance not only for the patient, but for the other relatives.
Read the article in Portuguese at: http://bit.ly/2sB0jVm